AFP and hepatocellular carcinoma: Despite the inclusion of patients who would typically be excluded from clinical trials of novel ICI-based therapies, the median PFS and OS noted in our cohort was similar to those of recently reported prospective clinical trials in both the 1st and 2nd line.1,2,5,6 Consistent with the natural history of HCC, we also observed a higher burden of disease, more extrahepatic disease, higher AFP, and worse liver function in patients who received ICI in later treatment lines.